• Abstract
• Full-Text PDF [4400 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Zhu, X
• He, Z
• Wu, J
• Yuan, J
• Wen, W
• Hu, Y
• Jiang, Y
• Lin, C
• Zhang, Q
• Lin, M
• Zhang, H
• Yang, W
• Chen, H
• Zhong, L
• She, Z
• Chen, S
• Lin, Y
• Li, M
• [+] on Google Scholar
• Zhu, X
• He, Z
• Wu, J
• Yuan, J
• Wen, W
• Hu, Y
• Jiang, Y
• Lin, C
• Zhang, Q
• Lin, M
• Zhang, H
• Yang, W
• Chen, H
• Zhong, L
• She, Z
• Chen, S
• Lin, Y
• Li, M
• [+] on PubMed
• Zhu, X
• He, Z
• Wu, J
• Yuan, J
• Wen, W
• Hu, Y
• Jiang, Y
• Lin, C
• Zhang, Q
• Lin, M
• Zhang, H
• Yang, W
• Chen, H
• Zhong, L
• She, Z
• Chen, S
• Lin, Y
• Li, M

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Mar. Drugs 2012, 10(4), 694-711; doi:10.3390/md10040694

Article

A Marine Anthraquinone SZ-685C Overrides Adriamycin-Resistance in Breast Cancer Cells through Suppressing Akt Signaling

Xun Zhu ^1,2,3,† , Zhenjian He ^1,2,3,† , Jueheng Wu ^1,2,3,† , Jie Yuan ^1,2,4 , Weitao Wen ^1,2,3 , Yiwen Hu ^1,2,3 , Yi Jiang ^5,6 , Cuiji Lin ^1,2,3 , Qianhui Zhang ^1,2 , Min Lin ^1,2 , Henan Zhang ^1,2 , Wan Yang ^1,2 , Hong Chen ^2,7 , Lili Zhong ^2,7 , Zhigang She ^2,7 , Shengping Chen ^1,2 , Yongcheng Lin ^2,7  and Mengfeng Li ^1,2,3,*

¹ Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510080, China ² Guangdong Province Key Laboratory of Functional Molecules in Oceanic Microorganism (Sun Yat-sen University), Bureau of Education, Guangzhou 510080, China ³ Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China ⁴ Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China ⁵ Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou 510080, China ⁶ Department of Cardiology, The First People’s Hospital of Zigong, 42 Shangyihao Road I, Zigong 643000, China ⁷ School of Chemistry and Chemical Engineering, Sun Yat-sen University, Guangzhou 510275, China ^† These authors contributed equally to this work.

* Author to whom correspondence should be addressed.

Received: 14 February 2012; in revised form: 13 March 2012 / Accepted: 14 March 2012 / Published: 23 March 2012

Download PDF Full-Text [4400 KB, uploaded 23 March 2012 15:54 CET]

Abstract: Breast cancer remains a major health problem worldwide. While chemotherapy represents an important therapeutic modality against breast cancer, limitations in the clinical use of chemotherapy remain formidable because of chemoresistance. The HER2/PI-3K/Akt pathway has been demonstrated to play a causal role in conferring a broad chemoresistance in breast cancer cells and thus justified to be a target for enhancing the effects of anti-breast cancer chemotherapies, such as adriamycin (ADR). Agents that can either enhance the effects of chemotherapeutics or overcome chemoresistance are urgently needed for the treatment of breast cancer. In this context, SZ-685C, an agent that has been previously shown, as such, to suppress Akt signaling, is expected to increase the efficacy of chemotherapy. Our current study investigated whether SZ-685C can override chemoresistance through inhibiting Akt signaling in human breast cancer cells. ADR-resistant cells derived from human breast cancer cell lines MCF-7, MCF-7/ADR and MCF-7/Akt, were used as models to test the effects of SZ-685C. We found that SZ-685C suppressed the Akt pathway and induced apoptosis in MCF-7/ADR and MCF-7/Akt cells that are resistant to ADR treatment, leading to antitumor effects both in vitro and in vivo. Our data suggest that use of SZ-685C might represent a potentially promising approach to the treatment of ADR-resistant breast cancer.

Keywords: SZ-685C; breast cancer; chemoresistance; Akt

Article Statistics

Cite This Article